

INCORPORATING BIOMARKERS IN CLL PATIENT TREATMENT

Focusing on *TP53* aberrations

Scientific Meeting INAB | CERTH

Saturday 4 June 2016

10.00 – 10.10	Introduction	Kostas Stamatopoulos
10.10 – 10.40	Treatment strategies in CLL patients with <i>TP53</i> aberrations	Niki Stavroyianni
10.40 – 11.40	Interactive Session I Case Presentation – Past and Present	Aliki Xochelli Maria Aggelopoulou Evdoxia Xatzizarisi Anastasia Mpanti
11.40 – 12.00	Coffee break	
12.00 – 12.30	Cytogenetics in aggressive CLL: is it just del(17p)?	Anastasia Athanasiadou
12.30 – 13.00	<i>TP53</i> aberrations in CLL: frequency and clinicobiological associations	Panagiotis Baliakas
13.00 – 14.00	Lunch Break	
14.00 – 14.45	The ERIC <i>TP53</i> Network: aims and activities	Sarka Pospisilova
14.45 – 15.45	Interactive session II <i>TP53</i> aberrations in clinical routine: reporting and translating results into clinical practice	Maria Roumeliotou Tasoula Touloumenidou Lila Papalexandri Panagiotis Baliakas
15.45 – 16.15	Coffee break	
16.15 – 16.45	The ERIC <i>TP53</i> Mutation Database	Sarka Pospisilova Anastasia Chatzidimitriou Eva Migga
16.45 – 17.10	ERIC Gene Panels	Lesley Ann Sutton
17.10 - 18.00	Current needs and possible solutions: suggestions for joint initiatives	Panagiotis Panayiotidis Kostas Stamatopoulos